Lonza has announced the acquisition of Swiss contract micronization company Micro-Macinazione. The company recently completed its acquisition of Capsugel which had acquired US micronization specialist Powdersize in 2015. Capsugel announced an expansion of its micronization capacity at the former Powdersize facility in Quakertown, PA in 2016, and that capacity came on line earlier this year, Lonza said.
Lonza Pharma & Biotech Chief Operating Officer Marc Funk commented, “With the acquisition of Micro-Macinazione, Lonza becomes the largest and most diversified provider of micronization services to the pharmaceutical industry. Micronization is an attractive technology for Lonza given its applications across many of the high growth areas of the pharma market. Micro-Macinazione provides micronization technology and expertise that complements our existing US capabilities and provides significant additional capacity to support our growth. Its micronization technology can also add value to other areas of Lonza’ business, including Health & Nutrition ingredients and excipients, enhancing the appeal of this bolt-on acquisition, which strengthens our position across the healthcare continuum.”
Micro-Macinazione CEO Markus Arigoni said, “Micro-Macinazione was founded in 1970 and has been a pioneer in the development of jet mill equipment and contract micronization services. We operate in a niche market with high growth expectations. Micronization is often seen as key to improving the bioavailability of the growing number of highly potent and complex APIs, which an increasing number of pharma and biotech companies are looking to develop. By combining with Lonza, we are creating a global leader with the ability to provide customers both in the US and Europe with access to the micronization technologies and manufacturing capabilities that they need to bring novel drugs to market faster and more efficiently.”
Read the Lonza press release.